A novel combined system for efficient nitrate removal using a continuous flow electrocoagulation and sand filtration (FECF) reactor: Statistical analysis by Taguchi design.

In this study, a new hybrid bench-scale electrocoagulation-sand filtration (FECF) reactor was developed for purifying nitrate-contaminated samples. Before and after electrochemical treatment, two sand filters were included in this continuous system to facilitate the purification procedure, and the contaminated water flows horizontally through the entire system according to a specific hydraulic gradient within the reactor, resulting in water purification. Significant improvement in treatment performance was observed due to the presence of metal hydroxides in the second filter media that were not fully involved in the electrocoagulation treatment.

Risk and Management of Intracerebral Hemorrhage in Patients with Bleeding Disorders.

Intracerebral hemorrhage (ICH) is the most dreaded complication, and the main cause of death, in patients with congenital bleeding disorders. ICH can occur in all congenital bleeding disorders, ranging from mild, like some platelet function disorders, to severe disorders such as hemophilia A, which can cause catastrophic hemorrhage. While extremely rare in mild bleeding disorders, ICH is common in severe coagulation factor (F) XIII deficiency.

The Role of MicroRNAs in Myeloproliferative Neoplasia.

MiRs are 17-25 nucleotide non-coding RNAs. These RNAs target approximately 80% of protein coding mRNAs. MiRs control gene expression and altered expression of them affects the development of cancer.

Diagnosis of factor XIII deficiency.

Background: Factor XIII (FXIII) deficiency is an extremely rare bleeding disorder with estimated incidence of one per two million. All routine coagulation tests are normal in FXIII deficiency (FXIIID), which complicates the diagnosis of this disorder. Precise diagnosis of FXIIID requires more specific tests, including qualitative tests as well as quantitative tests such as FXIII activity, antigen assays, and finally molecular studies to confirm FXIIID.